Clinical Trial Update: To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating YYB101 with irinotecan in metastatic or recurrent colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• YYB101 (YYB101)

Snippet

Sponsor: CellabMED | Conditions: Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | Phase 1, Phase 2 | Status: COMPLETED